Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Mutations in the MPL gene are frequently observed in myeloproliferative neoplasms (MPN), including primary myelofibrosis (PMF) and essential thrombocythaemia (ET).
• The W515L and W515K mutations in exon 10 of MPL are the most common, affecting the thrombopoietin receptor.
• The MPL S505N mutation, also in exon 10, is a founder mutation in familial thrombocythaemia, linked to thrombosis, splenomegaly, and fibrosis progression.

Purpose of the Study:

• To describe the diagnostic and clinical features of a rare case of sporadic MPL S505N-positive MPN.
• To analyze the clinical course and treatment response in a patient with MPL S505N MPN.
• To highlight the need for reporting more cases with this genotype to understand its specific clinical and morphological characteristics and refine therapeutic strategies.

Main Methods:

• Case report detailing the diagnosis and clinical course of an MPL S505N-positive MPN patient.
• Analysis of laboratory findings, clinical presentation, and bone marrow morphology.
• Review of treatment response and disease progression.

Main Results:

• The presented case exhibited diagnostic and treatment response features typical of essential thrombocythaemia (ET).
• Despite ET-like presentation, the patient showed evidence of progressive bone marrow fibrosis.
• The MPL S505N genotype in a sporadic MPN context requires further investigation.

Conclusions:

• The MPL S505N mutation can manifest as a rare cause of sporadic MPN with features overlapping with ET.
• Progressive bone marrow fibrosis may be a significant feature of MPL S505N MPN, even with an initial ET-like presentation.
• Accumulating data on MPL S505N MPN cases are crucial for defining specific clinical phenotypes and optimizing treatment.